The useful questions to ask before DSIP start with what's keeping you awake. They also cover breathing during sleep, other medicines, past treatment, and what would count as improvement. DSIP, short for delta sleep-inducing peptide, is a small chain of protein building blocks studied for sleep. Its name doesn't establish that it helps.

A visit gives the provider a chance to understand the problem before discussing a prescription. The broader questions to ask about peptide therapy cover pharmacy records and the prescription process. These ten questions keep the conversation focused on sleep.

Questions to ask before DSIP: the sleep complaint

1. What sleep problem are we actually evaluating?

The provider wants to know whether falling asleep, staying asleep, waking early, or feeling unrefreshed is the main complaint. Those descriptions help separate problems that can sound alike when summarized as bad sleep.

The National Institutes of Health's insomnia assessment guide describes this kind of history. Insomnia means difficulty sleeping despite having the opportunity to sleep, with consequences during the day. Having too little time available for sleep is a different starting point.

2. How long has this been happening, and how often?

The intake asks when the problem began, how many nights it happens, and whether anything changed around that time. That might include an illness, a new medicine, or a different work schedule.

A sleep diary records bedtimes, awakenings, naps, and how the next day feels. The clinician may use it to compare difficult nights with better ones. It makes the pattern easier to discuss than a single estimate of hours slept.

Breathing and daytime function

3. Does my snoring or waking up gasping need a separate assessment?

Loud snoring, choking, and breathing pauses noticed by a partner can raise concern for obstructive sleep apnea, repeated narrowing or closure of the airway during sleep. The provider asks about these signs because they can change the next step.

The American Academy of Sleep Medicine's (AASM) diagnostic guideline, Journal of Clinical Sleep Medicine, 2017 says a questionnaire alone cannot diagnose it. A clinician decides whether home testing or a laboratory sleep study fits the history. A DSIP discussion cannot supply that diagnosis.

4. Am I tired, or am I falling asleep during the day?

Feeling drained and unintentionally dozing are worth describing separately. The reviewer asks about naps, concentration, driving, and work that requires steady alertness.

Those answers show how much the sleep problem affects daily life. They also help the clinician decide whether another sleep disorder needs attention. A better-looking sleep record would mean little if staying awake during ordinary activities remained difficult.

Work schedules, alcohol, and other medicines

5. Could my schedule be part of the problem?

The provider compares workdays with days off, including overnight shifts, changing shifts, travel, and caregiving interruptions. Having an available sleep window matters as much as having a bedtime.

NIH's insomnia causes guide identifies shift work and changing routines as possible contributors. As of November 5, 2026, the day this article was written, the AASM's shift work disorder guideline, published October 24, 2026, treats sleepiness during a shift and poor sleep after it as separate problems, and every recommendation in it is conditional. A schedule problem can call for a different discussion from difficulty sleeping on a stable schedule. The intake is meant to uncover that difference.

6. How do alcohol and medicines that cause drowsiness fit into the review?

The clinician asks about amounts, timing, and changes in use. Sedatives are medicines that cause drowsiness; prescription sleep medicines and some nonprescription sleep aids belong in that conversation.

Alcohol use, recent reductions, and withdrawal symptoms also matter. Withdrawal means symptoms after reducing or stopping a substance the body has become used to. This history helps explain sleep disruption and existing drowsiness. It doesn't establish that a particular combination with DSIP has been tested.

7. Which other medicines and health conditions could change the assessment?

The review includes prescriptions, supplements, caffeine, other peptides, and recent medication changes. Pain, mood symptoms, pregnancy, and breathing or heart problems can also shape the evaluation.

The AASM's clinical evaluation guideline, Journal of Clinical Sleep Medicine, 2008 explains why medical and substance histories belong alongside sleep history. These questions help identify contributing problems. They aren't a fixed DSIP exclusion list, and routine sleep evaluation doesn't automatically require a standard blood-test panel.

Past treatment and realistic expectations

8. What have I already tried, and what happened?

The reviewer asks which treatments were tried, for how long, what changed, and why they ended. That includes cognitive behavioral therapy for insomnia, or CBT-I: structured treatment for habits and thoughts that keep insomnia going.

As of November 5, 2026, the day this article was written, the AASM's guideline published April 13, 2026 favors CBT-I plus insomnia medication over medication alone. It also favors CBT-I alone over routinely starting both together; both recommendations are conditional, meaning the clinician weighs individual circumstances. These findings concern the treatments studied, not DSIP.

9. What could we reasonably expect from DSIP's limited evidence?

The provider needs to know what improvement would matter: fewer long awakenings, less distress about sleep, or better daytime function. That makes expectations concrete before a treatment decision.

In Bes and colleagues' 1992 Neuropsychobiology study, 16 people with chronic insomnia received DSIP or placebo, an inactive comparison. Some recorded sleep measures favored DSIP, but the effects were weak and participants didn't rate their sleep as better. That small experiment cannot predict an individual's response. The DSIP benefits guide covers the wider evidence.

Follow-up and the prescribing decision

10. What would follow-up measure, and who would review a problem?

The discussion covers a review point, the sleep changes being tracked, daytime functioning, and how to contact the care team. Previous reactions to medicines also belong in the history.

The clinician can explain which new symptoms need attention and who handles medication questions. Our DSIP side effects guide separates reported effects from the larger gaps in safety data. A follow-up plan gives those observations somewhere to go.

What the answers help decide

DSIP prescribed through Promise is a compounded medication, prepared by a pharmacy for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved.

As of November 5, 2026, the day this article was written, the Department of Health and Human Services' October 30 notice describes a draft policy on when the department does not intend to take enforcement action over certain peptide compounding. DSIP is absent from Appendix A; the HHS peptide policy explainer covers its conditions.

A licensed provider may still prescribe — that decision is between you and your doctor.

The ten answers give the clinician a picture of the sleep complaint, competing explanations, and the limits of the evidence. That may lead to further questions, records, or a sleep evaluation. A prescription, if written, has its dose and timing set by the prescriber and is dispensed by a licensed U.S. compounding pharmacy.

At Promise, a licensed provider reviews every request, and not everyone qualifies.